Sugi Predict

Sugi Predict / Targets / SCN4A

SCN4A

Sodium channel protein type 4 subunit alpha · P35499 · SCN4A on Sugi Atlas →

38,275 patent compounds predicted against SCN4A, 21,377 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Mexiletine Mexiletine (SCHEMBL16081) 1.00 12/20
(R)-Mexiletine (R)-Mexiletine (SCHEMBL16082) 1.00 12/20
Mexiletine Mexiletine (SCHEMBL42226) 0.96 10/20
SCHEMBL57799 SCHEMBL57799 0.61 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL56787) 0.59 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL155367) 0.56 10/20
SCHEMBL147753 SCHEMBL147753 0.54 10/20
SCHEMBL287638 SCHEMBL287638 0.52 10/20
SCHEMBL293013 SCHEMBL293013 0.52 10/20
SCHEMBL56226 SCHEMBL56226 0.59 9/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL57277) 0.57 9/20
SCHEMBL624590 SCHEMBL624590 0.51 8/20
SCHEMBL64093 SCHEMBL64093 0.48 8/20
SCHEMBL598366 SCHEMBL598366 0.38 8/20
SCHEMBL623576 SCHEMBL623576 0.54 7/20
SCHEMBL43945 SCHEMBL43945 0.50 7/20
SCHEMBL170928 SCHEMBL170928 0.50 7/20
SCHEMBL176808 SCHEMBL176808 0.50 7/20
SCHEMBL515980 SCHEMBL515980 0.48 7/20
SCHEMBL266309 SCHEMBL266309 0.45 7/20

Clinical trials — most relevant to SCN4A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations PHASE4COMPLETED
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome PHASE3RECRUITING
MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias PHASE3UNKNOWN
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety PHASE3RECRUITING
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome PHASE1/PHASE2COMPLETED
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome PHASE2COMPLETED
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies PHASE2WITHDRAWN
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A nanCOMPLETED
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC. nanNOT_YET_RECRUITING
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom nanRECRUITING
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy nanCOMPLETED
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA) nanCOMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation nanRECRUITING
Treatment of Gait Disorders in Children With Dravet Syndrome nanCOMPLETED
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients nanCOMPLETED
The Natural History of TRPV4 Neuropathy nanRECRUITING
Painful Channelopathies Study nanUNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
Exploring the Genetics of Neuropathic Pain nanRECRUITING
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SCN4A binder may also engage these)

ProteinNameSimilarity
P15390 — 1.000 P15390 →
Q9ER60 — 1.000 Q9ER60 →
Q28371 — 1.000 Q28371 →
Q62968 — 1.000 Q62968 →
P15389 — 0.999 P15389 →
SCN5A Sodium channel protein type 5 subunit alpha 0.999 landscape →
Q6QIY3 — 0.998 Q6QIY3 →
Q2XVR7 — 0.997 Q2XVR7 →
SCN2A Sodium channel protein type 2 subunit alpha 0.997 landscape →
Q9JJV9 — 0.997 Q9JJV9 →
SCN3A Sodium channel protein type 3 subunit alpha 0.996 landscape →
SCN10A Sodium channel protein type 10 subunit alpha 0.996 landscape →
Q2XVR3 — 0.995 Q2XVR3 →
O88420 — 0.995 O88420 →
P04775 — 0.995 P04775 →
P08104 — 0.994 P08104 →
A2ASI5 — 0.993 A2ASI5 →
O46669 — 0.993 O46669 →
B1AWN6 — 0.993 B1AWN6 →
Q28644 — 0.993 Q28644 →
Q2XVR6 — 0.992 Q2XVR6 →
Q62205 — 0.992 Q62205 →
Q2XVR5 — 0.992 Q2XVR5 →
Q9WTU3 — 0.992 Q9WTU3 →
A2APX8 — 0.992 A2APX8 →
P0DMA5 — 0.991 P0DMA5 →
P02719 — 0.991 P02719 →
SCN9A Sodium channel protein type 9 subunit alpha 0.990 landscape →
Q9R053 — 0.990 Q9R053 →
SCN1A Sodium channel protein type 1 subunit alpha 0.990 landscape →